Afatinib 30 mg in the treatment of common and uncommon  EGFR -mutated advanced lung adenocarcinomas: a retrospective, single-center, longitudinal study

Afatinib 30 mg in the treatment of common and uncommon EGFR-mutated advanced lung adenocarcinomas: a retrospective, single-center, longitudinal study

Jie Qian, Xuanting Ye, Aimi Huang, Ruoyan Qin, Yuqing Cai, Yiqian Xue, Shi Zhang, Weimin Wang, Liwen Xiong, Aiqin Gu